PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...
News Medical on MSN14d
Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeuticPheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received ...
Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its small molecule therapeutic, PTD802. The ...
Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's MHRA for its small molecule therapeutic, ...
A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence ...
A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback